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“Indefinite for Dysplasia” in Barrett’s Esophagus:
Inflammation and DNA Content Abnormality are
Significant Predictors of Early Detection of Neoplasia
Won-Tak Choi, MD, PhD1, Mary J. Emond, PhD2, Peter S. Rabinovitch, MD, PhD1, Joseph Ahn, MD3, Melissa P. Upton, MD1 and
Maria Westerhoff, MD1
BACKGROUND: Dysplasia arising from Barrett’s esophagus precedes esophageal adenocarcinoma (EAC). Cases that are difficult
to diagnose as dysplastic, especially in the setting of inflammation, may be designated “indefinite for dysplasia (IND).” Although
flow cytometric analysis of DNA content has shown some promise in detecting EAC, there are few reports that have specifically
evaluated the outcome of IND.
AIMS AND METHODS: We analyzed a series of 96 IND patients seen at the University of Washington between 2005 and 2013 to
determine the outcome of IND and to identify factors (including histologic features and DNA flow cytometric data) associated with
subsequent detection of neoplasia.
RESULTS: Twenty-five percent of IND cases were found to have low-grade dysplasia, high-grade dysplasia (HGD), or EAC within
1 year, with 37% and 47% detected within 2 and 3 years, respectively. The 1-, 2-, and 3-year detection rates of HGD or EAC were 10%,
13%, and 20%, respectively. Active inflammation (hazard ratio (HR)= 3.4, P= 0.0005) and abnormal DNA content (HR= 5.7,
P= 0.003) were significant risk factors of neoplasia. When active inflammation and DNA flow cytometric results were considered
together, the HR for the combined markers was 18.8 (Po0.0001). The sensitivity and specificity of the combined markers for
predicting detection of subsequent neoplasia within 3 years were 100% and 60%, respectively, with 100% negative and 89%
positive predictive values.
CONCLUSIONS: Histology with the support of DNA flow cytometry can identify a subset of IND patients who may have a higher risk
for subsequent detection of neoplasia.
Clinical and Translational Gastroenterology (2015) 6, e81; doi:10.1038/ctg.2015.7; published online 12 March 2015
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INTRODUCTION
Barrett’s esophagus (BE) is a major risk factor for the develop-
ment of esophageal adenocarcinoma (EAC).1–3 The incidence of
EAC has continued to rise in the United States, at least until the
year 2001. From 1975 to 2001, its incidence rose approximately
sixfold, even outpacing those of melanoma, breast cancer,
or prostate cancer.4 Most EACs develop in the setting of BE
through the chronic gastroesophageal reflux disease-metaplasia-
dysplasia-carcinoma sequence.1 The American College of
Gastroenterology defines BE as endoscopically visible columnar
epithelium extending upwards from the gastroesophageal junc-
tion that is histologically confirmed to have intestinal metaplasia
(goblet cells), the conventionally accepted preneoplastic lesion
for EAC in mucosal biopsy specimens.3,5,6
Multiple retrospective studies have demonstrated that EAC
detected by endoscopic surveillance has lower staging with
superior survival than EAC discovered without surveillance.7,8
This observation has led to the current practice of endoscopic
surveillance and therapy for BE patients, with the appropriate
surveillance interval typically determined by the grade of
dysplasia on an initial biopsy; more frequent surveillance and/
or ablation therapy is needed with a higher grade of dysplasia.3
Dysplasia in BE is defined as neoplastic epithelium confined
to the basement membrane, and classified as negative for
dysplasia, indefinite for dysplasia (IND), low-grade dysplasia
(LGD), and high-grade dysplasia (HGD).1 In LGD, there is a
distinct lack of surface maturation with atypical nuclei limited to
the basal portion of the cell cytoplasm while preserving crypt
architecture.1 In contrast, HGD is defined by the presence of full-
thickness nuclear stratification, pleomorphism, atypical mitoses,
and increased cytologic and/or architectural complexity, including
back-to-back gland formations and increased crypt complexity.1
The category of IND is used most often in the setting of
inflammation/ulceration where a definite distinction between
regeneration and dysplasia cannot be made with certainty.
However, IND is also used when an accurate diagnosis cannot
be made due to technical issues, including the lack of surface
epithelium, marked cautery effect, or tangential section.1
Interobserver variability in the diagnosis of dysplasia, especially
IND, has been reported among pathologists.9,10
There are few reliable biomarkers/techniques to aid in
differentiating non-dysplastic from dysplastic epithelium.
Among the proposed markers for predicting malignant
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progression, the use of nuclear DNA content abnormities
(such as aneuploidy) has shown some promise in predicting
cancer risk.1,3 Reid et al.11 demonstrated that by using flow
cytometry to measure the DNA content in the mucosa,
patients who had negative, IND, or LGD biopsies without
increased 4N or aneuploidy had a 0% 5-year cumulative
cancer incidence, whereas patients with baseline increased
4N, aneuploidy, and HGD had 5-year cancer incidences of
56%, 43%, and 59%, respectively. However, in that study, DNA
flow cytometry was evaluated as a potential objective marker
for predicting progression to EAC, whereas in current clinical
practice, determining risk for subsequent detection of LGD
and HGD is equally important, as the grade of dysplasia
dictates appropriate surveillance interval, and HGD or early
EAC usually requires either nonsurgical ablation therapy or
resection.2,3,12
Regarding IND, studies that have specifically evaluated the
natural history or outcome of IND, including risk for subse-
quent detection of dysplasia or EAC, have been extremely
limited. Available data on the neoplastic risk of IND have
usually been provided only as a small subset of cases within
the context of a larger dysplasia-endpoint study. In one study,
Montgomery et al.13 showed that ~ 12% of IND cases
developed EAC within 3 years, similar to the 8% progression
rate for LGD. However, these rateswere based on only a single
patient that progressed to neoplasia in each group.13 Younes
et al.14 also reported that only 1 (2%) of 48 IND patients
progressed to HGD or EAC after a mean follow-up of
41 months, but again, this was based on one patient that
progressed to neoplasia, with limited follow-up time for the
majority of 48 IND patients.
There are many endoscopic and pathologic factors that may
affect the outcome results of IND, including the number of
biopsies (sampling error), frequency/interval of surveillance
endoscopy, and correct pathologic interpretation (dysplasia
detected on the follow-up biopsies of IND being true dysplasia
in the first place vs subsequently developed, histologically
confirmed dysplasia).1 As a result, the management of
IND with endoscopic surveillance varies among different
institutions. In fact, the guidelines for the diagnosis, surveil-
lance, and therapy of BE issued by the American College of
Gastroenterology (in 2008)3 and the American Gastroenter-
ological Association (in 2011)2 do not provide specific
guidance for the management of IND.
This study sought to determine the outcome of IND and to
identify factors predictive of subsequent detection of dysplasia
or EAC occurring within 3 years of initial IND biopsy. We
analyzed follow-up data on 96 established BE patients who
had diagnoses of IND between 2005 and 2013. Specifically,
we aimed to correlate subsequent detection of LGD, HGD, or
EAC with histological active (neutrophilic) inflammation, DNA
flow cytometric data (aneuploidy and/or increased 4N frac-
tion), and endoscopic findings in a statistically rigorous
manner.
METHODS
Patients and data collection. Using our pathology informa-
tion system (Power Path, Sunguest, Tucson, AZ, USA), we
performed a review involving 96 patients with histologically
confirmed Barrett’s metaplasia who were categorized as
having IND and had follow-up biopsies, collected at the
University of Washington and Harborview Medical Centers
between 2005 and 2013. Our study was approved by the
University of Washington Institutional Review Board for
human subjects research, #46704. Table 1 shows demo-
graphic characteristics of this cohort. For inclusion in this
study, patients with a diagnosis of IND must have had follow-
up biopsies. One endpoint of this was subsequent histologi-
cal detection of any neoplasia, including LGD, HGD, or EAC;
the second endpoint was subsequent histological detection of
higher-grade neoplasia, comprising HGD or EAC. Hospital
clinical and Power Path electronic medical records were
further reviewed for these patients, and we retrieved pertinent
data, including active (neutrophilic) inflammation in the
area of IND, DNA flow cytometric data (aneuploidy and/or
increased 4N fraction), and endoscopic findings (length of BE
segment (shorto3 cm and long44 cm of Barrett’s mucosa),
nodule/nodularity, and hiatal hernia). All 96 IND cases were
reviewed by gastrointestinal pathologists at the University of
Washington Medical Center. IND was defined as an area of
Table 1 Characteristics of 96 patients diagnosed with IND at the University of Washington and Harborview Medical Centers between 2005 and 2013
Entire cohort
(N= 96)
Cohort with baseline
inflammation (N=46)
Cohort without baseline
inflammation (N= 50)
Mean age, years (range) 63 (39–86) 62 (39–86) 63 (43–82)
Gender 75 males, 21 females 36 males, 10 females 39 males, 11 females
Mean weight, kg (range) 87 (54–134) 88 (58–131) 87 (54–134)
Mean BMI, kg/m2 (range) 28 (19–48) 29 (19–48) 27 (21–34)
Race 55 Caucasians
41 non-Caucasians
21 Caucasians
25 non-Caucasians
34 Caucasians
16 non-Caucasians
PPI use 64% (61/96) 54% (25/46) 72% (36/50)
Median time interval, months to first surveillance
following IND (range)
7 (0.5–49) 5.5 (0.5–39.5) 9 (0.5–49)
Median time interval between all endoscopies,
months (range)
8.5 (0.5–60) 7 (0.5–40.5) 12 (0.5–60)
Mean number of follow-up endoscopies from
IND to LGD/HGD/EAC (range)
1.7 (1–6) 1.9 (1–6) 1.4 (1–4)
BMI, body mass index; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; PPI, proton pump
inhibitor.
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atypical surface and crypt epithelium suggestive of possible
dysplasia, but with interpretation limited due to associated
inflammation (raising the possibility of reactive atypia),
ulceration, or technical issues, including lack of surface
epithelium, marked cautery effect, or tangential sectioning,
reducing the certainty of the evaluation of the biopsy.1
DNA content flow cytometry. Among the 96 IND cases, 39
patients (41%) had concurrent flow cytometric DNA analysis.
There is no established guideline on the appropriate use of
DNA flow cytometry for the management of BE patients.
Therefore, DNA flow cytometric analysis was performed for a
variety of reasons, including the provider’s clinical suspicion
of dysplasia based on endoscopic findings, easy access to
the DNA flow cytometry laboratory at the University of
Washington, potential applications of DNA content abnorm-
alities in predicting cancer risk, and/or the patient’s desire for
the testing. As described previously,11 one half of the biopsy
specimen was fixed in formalin for histological examination,
and the other half was processed for flow cytometry and
analyzed by the computer program Multicycle (Phoenix Flow
Systems, San Diego, CA). An aneuploidy population was
defined and described previously.15,16 The finding of 4N
fractions greater than 6% of the nuclei (within the range of
3.85N to 4.1N) was classified as abnormal. Flow cytometric
histograms were interpreted by one pathologist (PSR)
blinded to the histologic results.
Statistical analysis. Statistical analysis was performed
using methods appropriate for censored data (Kaplan–Meier
curves (KM) and the Cox proportional hazards model), as
follow-up time varied among patients (minimum= 0.3 months
and maximum=88 months). The presence of active inflam-
mation and abnormal DNA flow cytometric findings were
assessed using both univariate and multivariate Cox models.
The KM and Cox analysis utilized the entire follow-up time
period available for each person; the KM provides estimates
of detection over the entire range of follow-up times with
larger confidence intervals (CIs) as fewer people become at
risk at later times, and the hazard ratio (HR) estimate in the
Cox proportional hazards model is a weighted average of the
hazard at each failure time, weighted according to the
number of individuals still at risk.17 Analysis was performed
using the “survival,” “rms,” and “Hmisc” packages in R (www.r-
project.org). For primary analyses, only patients with the
complete data were included and reported. Because a
significant number of patients did not have DNA flow
cytometry assessed at baseline IND diagnosis, we used a
multiple imputation method to obtain an unbiased estimate of
the HR by jointly estimating the missing data for 23
individuals who had no DNA flow cytometric analysis and
were negative for active inflammation at baseline. Briefly, the
probability of a DNA flow cytometric abnormality for each of
these 23 patients was calculated using Bayes’ Theorem on
the basis of his/her censoring or event time and the KM
estimates of detection from the complete data only.18 Missing
data were drawn from these distributions for imputations
(N=1000), and the HR was calculated for each draw,
providing a mean HR as the unbiased imputation estimate.
The variance estimate for the imputation-estimated HR
was calculated as a sum that incorporated the error vari-
ability from the observed data plus the error variability
introduced by estimating the missing DNA flow cytometric
measurements.18
The results from the imputation analysis were compared
with the KM estimates obtained from the conservative method
of classifying all patients with missing DNA flow cytometric
data as negative for DNA content abnormalities. This
constitutes misclassification of patients as normal who might
not be normal, which is well known to result in attenuated/
conservative estimates of risk (HR estimate that is biased
downward from the truth, less separation between groups and
a larger P-value).19 This latter method allows one to assess
the effects of the multiple imputation analysis relative to the
conservative assumption of no DNA flow cytometric abnorm-
alities among the 23 patients. Furthermore, the misclassifica-
tion method parallels the reality of the current practice in BE
and provides an estimate of the actual predictive power of the
DNA flow cytometry combined with active inflammation over a
number of clinics that do not have access to a DNA flow
cytometry laboratory, while information on active inflammation
is available. The CIs for the imputation-based estimate are no
more narrow than for the estimate from the analysis that
(incorrectly) assumes all missing DNA flow cytometric
measurements were negative, as no more real data are
obtained via imputation, but the imputation-based estimate is
shifted away from the biased estimate obtained under this
incorrect assumption.
For estimates of 1-, 2-, and 3-year detection/progression
and for the overall detection/progression KM estimates, only
patients having at least one follow-up endoscopy within the
respective time interval or who were known not to progress in
that interval were included in the risk set. There were N=70,
N= 48, and N=42 patients with appropriate follow-up time for
estimates of 1-, 2-, and 3-year detection/progression esti-
mates for dysplasia or EAC. The 42 patients who had at least 3
years of follow-up were used to estimate 3-year sensitivity,
specificity, positive predictive value, and negative predictive
value of the combined active inflammation and DNA flow
cytometric markers for subsequent detection of LGD, HGD, or
EAC. The CIs for these proportions were obtained by Wilson’s
method.
RESULTS
Detection of LGD, HGD, or EAC. The overall demographic
characteristics of the cohort and those divided by the
presence or absence of active inflammation at baseline are
shown in Table 1. The use of proton pump inhibitor was
slightly higher among patients without active inflammation at
baseline, but the difference was not statistically significant
between cohort with and without baseline active inflammation
(P= 0.09). Mean and median follow-up times were 14
and 10 months, respectively, for the 96 IND patients
(minimum=0.3 months and maximum=88 months). Regard-
ing follow-up, 70, 48, and 42 patients had follow-up time
appropriate for 1-, 2-, and 3-year risk estimates, respectively,
for subsequent detection of dysplasia or EAC. A total of 35
patients had histological evidence of LGD, HGD, or EAC. The
“Indefinite for Dysplasia” in Barrett’s Esophagus
Choi et al.
3
Clinical and Translational Gastroenterology
KM analysis showed that 1-, 2-, and 3-year detection rates of
LGD, HGD, or EAC were 25%, 37%, and 47%, respectively
(95% CIs= (14%, 34%), (24%, 48%), and (31%, 60%),
respectively, Figure 1a). The presence of active inflammation
at baseline (in 46 of 96 patients) was found to be a highly
significant predictor of early detection of LGD, HGD, or EAC
(Figure 1b; Table 2). The univariate HR associated with active
inflammation was estimated to be 3.4 from the Cox model
(P=0.0005, 95% CI= (1.7, 7.5); Table 2).
Both aneuploidy and elevated 4N fraction were also
associated with an increased risk of subsequent detection of
dysplasia or EAC. Patients with aneuploidy had an estimated
HR of 4.0 (P=0.007, 95% CI= (1.4, 12.1)), whereas patients
with elevated 4N fraction had an HR of 4.4 (P=0.005, 95%
CI= (1.4, 13.6); Figure 1c,Table 2). For patientswho had either
DNA flow cytometric abnormality or active inflammation, the
difference in the detection rate of neoplasia was highly
significant (P=0.003) among the 39 patients who had DNA
flow cytometric data available, but the HR was not estimable
(infinite), because no patients without any of the abnormalities
were found to have dysplasia or EAC during follow-up
(Figure 1d,Table 2). Patients with neither active inflammation
nor a DNA flow cytometric abnormality had a stable 1-, 2-, and
3-year detection rates of 0%, whereas patients with any of
these risk factors had 1-, 2-, and 3-year detection rates of 18%,
45%, and 50%, respectively (Figure 1d).
Figure 1 (a) Overall detection of LGD, HGD, or EAC in BE patients with IND; (b) detection of LGD, HGD, or EAC in IND patients with active inflammation at baseline; (c)
detection of LGD, HGD, or EAC in IND patients with abnormal DNA flow cytometric results at baseline (either elevated 4N fraction or aneuploidy); and (d) detection of LGD, HGD,
or EAC in IND patients with either a DNA flow cytometric abnormality or active inflammation at baseline. Each tick represents a person being censored, and the number of people
remaining at risk at each 10-month interval is indicated below that axis. The estimates after 60 months have wide CIs (thus more uncertainty). BE, Barrett’s esophagus;
CI, confidence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.
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Table 2 Univariate and multivariate Cox proportional hazards models with LGD/HGD/EAC or HGD/EAC as the outcome
Univariate model variable Group (N) Outcome
Detection of LGD/HGD/EAC Detection of HGD/EAC
P value HR 95% CI P value HR 95% CI
Inflammation No 50
Inflammation Yes 46 0.0005 3.4 (1.7, 7.5) 0.003 5.8 (1.6, 21.4)]
Aneuploidy No 31
Aneuploidy Yes 8 0.007 4.0 (1.4, 12.1) 0.13 3.8 (0.6, 23.7)
Elevated 4N No 27
Elevated 4N Yes 12 0.005 4.4 (1.4, 13.6) 0.84 1.2 (0.2, 7.3)
Elevated 4N or aneuploidy No 24
Elevated 4N or aneuploidy Yes 15 0.003 5.7 (1.6, 20.9) 0.13 4.8 (0.5, 43.5)
Age460 No 44
Age460 Yes 52 0.58 0.8 (0.4, 1.6) 0.28 0.57 (0.21, 1.6)
Inflammation or flow abnormality No 16
Inflammation or flow abnormality Yes 23 0.003 Infinite NA 0.11 Infinite NA
Inflammation or flow abnormality No* 39
Inflammation or flow abnormality Yes* 61 o0.0001 18.8 (4.5, 79) o0.02 10.3 (1.7, 63)
BE length long No 29
BE length long Yes 30 0.43 1.4 (0.6, 3.4) 0.19 2.5 (0.6, 10.4)
Nodule No 52
Nodule Yes 7 0.97 1 (0.2, 4.2) 0.93 1.1 (0.1, 8.9)
Hernia No 22
Hernia Yes 37 0.55 1.4 (0.5, 3.7) 0.66 1.4 (0.3, 6.9)
Multivariate Cox model (N= 39, 12 events) (N= 39, 5 events)
Inflammation 0.02 4.9 (1.4, 17.8) 0.04 15.1 (1.1, 213)
Any flow abnormality 0.002 9.7 (2.3, 40.1) 0.06 11.5 (0.8, 157)
BE, Barrett’s esophagus; CI, confidence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; HR, hazards ratio; LGD, low-grade dysplasia; NA,
not applicable
*Based on a multiple imputation (unbiased) menthod.
Figure 2 (a) Detection of LGD, HGD, or EAC in IND patients with either a DNA flow cytometric abnormality or active inflammation at baseline, using a multiple imputation
(unbiased) method; and (b) detection of LGD, HGD, or EAC in IND patients with either a DNA flow cytometric abnormality or active inflammation at baseline, assuming that
patients without DNA flow cytometric data had no DNA content abnormalities at baseline. This assumption increases the sample size relative to the Figure 1d (thus, providing
more statistical power to reject the null hypothesis for the combined markers), but diminishes the true difference between groups due to measurement error. Each tick represents
a person being censored, and the number of people remaining at risk at each 10-month interval is indicated below that axis. The estimates after 60 months have wide CIs (thus
more uncertainty). CI, confidence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.
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To obtain an estimate of the HR for the combination markers
of active inflammation and DNA flow cytometric abnormality, a
multiple imputation (unbiased) method was used with a large
number of imputations (1,000) to account for imputation error,
resulting in an estimated HR of 18.8 (Po0.0001, 95%
CI= (4.5, 79); Figure 2a,Table 2). For comparison, all patients
with missing DNA flow cytometric data were conservatively
classified as negative for DNA flow abnormalities, and the KM
plots were redrawn. This conservative classification method
results in estimates of the HR and separation between groups
that are biased downward relative to knowing the true DNA
flow cytometric measurements. The comparison shows a
slight but meaningful difference (Figure 2b): 39 of 96 patients
were classified as having neither active inflammation nor DNA
flow cytometric abnormality with the conservative classifica-
tion (HR= 5.7 for the latter), whereas an average of 35 patients
were classified as having no abnormality in the imputation
analysis. As expected, the imputation method estimates that 4
additional patients had DNA flow cytometric abnormalities, on
average, among the 23 missing DNA flow cytometric data with
no active inflammation at baseline. Using only patients whose
first follow-up status was known within 3 years (N= 42),
estimated sensitivity of the combined markers for detection of
LGD, HGD, or EAC within 3 years was 100% (95% CI= (91%,
100%)) with a specificity of 60% (95%CI= (31%, 83%)), 100%
negative predictive value (95% CI= (61%, 100%)), and 89%
Figure 3 (a) Overall detection of HGD or EAC in BE patients with IND; (b) detection of HGD or EAC in IND patients with active inflammation at baseline; (c) detection of HGD
or EAC in IND patients with abnormal DNA flow cytometric results at baseline (either elevated 4N fraction or aneuploidy); and (d) detection of HGD or EAC in IND patients with
either a DNA flow cytometric abnormality or active inflammation at baseline. Each tick represents a person being censored, and the number of people remaining at risk at each 10-
month interval is indicated below that axis. The estimates after 60 months have wide CIs (thus more uncertainty). BE, Barrett’s esophagus; CI, confidence interval; EAC,
esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia.
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positive predictive value (95% CI= (76%, 96%)). In addition to
this assessment of joint predictive capacity, we assessed the
independent contribution of DNA flow cytometric abnormal-
ities and active inflammation by entering both simultaneously
in the Cox model (using patients with complete data only), and
both were independently associated with subsequent detec-
tion of dysplasia or EAC with respective HR= 9.7 (P=0.002,
95% CI= (2.3, 40.1)) and HR= 4.9 (P=0.02, 95% CI= (1.4,
17.8); Table 2).
As the presence of longer BE segment, nodule/nodularity,
and hiatus hernia have been previously reported as major
risk factors for the development of BE, dysplasia, and/or
EAC,1,20,21 the available endoscopic reports for our cohort of
IND patients were reviewed. Interestingly, the length of BE
segment (HR=1.4, P= 0.43, 95% CI= (0.6, 3.4)), nodule/
nodularity (HR=1, P=0.97, 95% CI= (0.2, 4.2)), and hiatal
hernia (HR= 0.55, Po0.55, 95% CI= (0.5, 3.7)) were not
associated with subsequent detection of dysplasia or EAC
within the study period. Our finding that 63% of this cohort had
hiatal hernia (Table 2) is consistent with previous reports that
the presence of hiatus hernia is a major risk factor for the
development of BE.1,21 However, it should be noted that
because the study was designed to identify factors predictive
of subsequent detection of neoplasia occurring within 3 years
of initial IND biopsy, we cannot completely exclude the
possibility that the presence of longer BE segment, nodule/
nodularity, and/or hiatal hernia may be associated with an
increased risk of subsequent detection of neoplasia with a
longer follow-up time.
Detection of HGD or EAC. The 1-, 2-, and 3-year detection
rates of HGD or EAC were 10%, 13%, and 20%, respectively
(95% CIs= (3%, 16%), (5%, 20%), and (8%, 31%),
Figure 3a). The presence of active inflammation (in 46 of
96 patients) was also found to be a significant predictor of
subsequent finding of HGD or EAC (Figure 3b,Table 2). The
univariate HR for the detection of HGD or EAC associated
with active inflammation was estimated to be 5.8 from the
Cox model (P= 0.003, 95% CI= (1.6, 21.4); Table 2). Patients
with aneuploidy had an estimated HR of 3.8 that was close to
being statistically significant (P= 0.13, 95% CI= (0.6, 23.7)),
whereas patients with elevated 4N fraction did not show an
elevated risk of subsequent detection of HGD or EAC in this
sample (HR= 1.2, P=0.84, 95% CI= (0.2, 7.3); Figure 3c,
Table 2). However, there were only five individuals in whom
HGD or EAC was detected, among those who had DNA flow
cytometric data available, limiting the power of statistical tests
and estimation of the effects of DNA flow cytometric
variables. For patients who had either DNA content abnorm-
alities or active inflammation, the difference in the detection
rate between those with subsequent neoplasia and those
without neoplasia was close to being statistically significant
(P= 0.11), but the HR was not estimable with the complete
data only (infinite; Figure 3d), as none of the patients who had
normal DNA flow cytometry without active inflammation
at baseline were subsequently found to have HGD or EAC.
The imputation-based HR estimate was 10.3 (Po0.02,
95% CI= (1.7, 63); Figure 4a, Table 2). The imputation
results were consistent with the expected values based on
misclassification/conservative classification of patients with
missing DNA flow cytometric data as negative for DNA
content abnormalities (Figure 4b); the former gives somewhat
better separation between groups than the latter (HR=4.8 for
the latter). The length of BE segment (HR= 2.5, P=0.19,
Figure 4 (a) Detection of HGD or EAC in IND patients with either a DNA flow cytometric abnormality or active inflammation at baseline, using a multiple imputation (unbiased)
method; and (b) detection of HGD or EAC in IND patients with either a DNA flow cytometric abnormality or active inflammation at baseline, assuming that patients without DNA
flow cytometric data had no DNA content abnormalities at baseline. This assumption increases the sample size relative to the Figure 3d (thus, providing more statistical power to
reject the null hypothesis for the combined markers), but diminishes the true difference between groups due to measurement error. Each tick represents a person being censored,
and the number of people remaining at risk at each 10-month interval is indicated below that axis. The estimates after 60 months have wide CIs (thus more uncertainty).
CI, confidence interval; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia.
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95% CI= (0.6, 10.4)), nodule/nodularity (HR=1.1, P= 0.93,
95% CI= (0.1, 8.9)), and hiatal hernia (HR=1.4, Po0.66,
95% CI= (0.3, 6.9)) were not significantly associated with an
increased risk of subsequent detection of neoplasia.
DISCUSSION
EAC is theorized to progress sequentially from metaplasia to
dysplasia and ultimately to EAC.1,21 Most patients are followed
up by endoscopic biopsy surveillance, and the degree of
dysplasia usually determines the interval between endoscopic
procedures.2,3 The epithelial atypia should involve not only the
crypts but also the surface epithelium to meet the criteria for a
diagnosis of dysplasia in Barrett’s metaplasia.1 The recogni-
tion of HGD or early EAC usually prompts either resection or
nonsurgical ablation therapy.2,3,12
Although a diagnosis of IND may very well harbor a
neoplasia and portend an increased risk of subsequently
developing malignancy, there are few reports regarding the
natural history of IND. Data on the neoplastic risk of IND have
usually been provided within the context of larger dysplasia
studies, which suggest that the risk of progression from IND to
HGD or EAC ranges from 2 to 12% (with a mean follow-up of 3
years).13,14 However, the sample sizes and follow-up time
were very limited in these studies, and none has assessed the
potential association between active inflammation or DNA flow
cytometric abnormalities and detection of subsequent dyspla-
sia or EAC. In addition, even when the surveillance strategy
follows the Seattle protocol, with four-quadrant biopsies taken
in every centimeter of columnar-lined esophagus, the majority
of the esophageal mucosa is not sampled. Therefore, on the
basis of sampling differences alone, it is not possible to
distinguish progression from detection. In other words, a
patient with IND on one set of biopsies might have unsampled
neoplasia elsewhere in the esophagus. For this reason, we
are careful to describe the finding of neoplasia within 4 years of
the biopsy finding of IND as early detection. Some of these
patients may represent true progression in the form of
subsequent neoplastic development; however, the finding of
neoplasia within 3–4 years of the IND biopsy may represent
sampling differences. Our data show that 20% of IND had
detection of HGD or EAC within 3 years, and that active
inflammation and DNA flow cytometric abnormalities are
significant predictors of high-grade neoplasia on subsequent
biopsies. Furthermore, a combination of DNA flow cytometric
abnormality and active inflammation is even more highly
predictive of detection of high-grade neoplasia within 3 years
(Table 2).
The diagnostic category of IND is used most often in the
setting in which there is cytological atypia suggestive of
possible dysplasia, but with associated inflammation, ulcera-
tion, or technical issues, including lack of surface epithelium,
marked cautery effect, or tangential sectioning, which limits
evaluation of the surface or of the biopsy.1 Interestingly, our
data demonstrate that active inflammation, although creating
diagnostic problems, is a significant risk factor for subsequent
dysplasia or EAC (Figures 1b and 3b,Table 2), suggesting that
active inflammation may serve as an important histologic
marker for the detection of unsampled high-grade neoplasia.
Although one may argue that active inflammation may be
simply interfering with the reading of true dysplasia, the fact
that many patients with active inflammation at baseline are
found to have dysplasia several months to years afterwards
further highlights the importance of active inflammation as a
major risk factor for high-grade neoplasia. As such, close
follow-up is warranted for patients with IND in the setting of
significant active inflammation.
Aside from morphologic evaluation of dysplasia, evaluation
of DNA content by flow cytometry has shown consistent
results as a strong predictor of EAC. Reid et al.16 reported that
9 of 13 patients who showed aneuploidy or increased G2/
tetraploidy populations in their initial DNA flow cytometric
analysis developed HGD or EAC on follow-up (for a mean
interval of 34 months), whereas none of 49 patients without
these abnormalities progressed to HGD or EAC. Our data
extend these observations by showing that there is a
significant correlation between the abnormal results of the
DNA flow cytometric study and IND that were found to have
dysplasia or EACwithin 3 years. Both aneuploidy and elevated
4N fraction were associated with an increased risk in IND
patients (Figure 1c,Table 2). The data further suggest that the
use of flow cytometry for the analysis of nuclear DNA content
and cell cycle parameters could have an important role in
identifying a subset of IND patientswith a higher risk of HGD or
EAC, thus strengthening the vigilance for surveillance endo-
scopy in this high-risk group. More importantly, when active
inflammation and abnormal DNA flow cytometric results were
considered together, the sensitivity of the combined markers
for the detection of LGD, HGD, or EAC within 3 years was
100% (95% CI= (91%, 100%)) with a specificity of 60%
(95% CI= (31%, 83%)), 100% negative predictive value (95%
CI= (61%, 100%)), and 89% positive predictive value (95%
CI= (76%, 96%)).
The management of IND with endoscopic surveillance is
variable among different institutions. Some are treated more
aggressively and re-biopsied in 3–6 months, whereas others
are treated similarly to those with LGD with annual endosco-
pies until no dysplasia is detected. As such, the clinical
implications of our findings may largely depend on how this
IND category is utilized for clinical follow-up and therapy. On
the basis of our findings showing that patients with active
inflammation and/or abnormal DNA flow cytometric results
have dysplasia or EAC on biopsies taken within 3 years of the
IND finding (Figures 1d and 3d), an IND diagnosismaywarrant
shorter follow-up surveillance intervals, especially in the
setting of active inflammation and DNA content abnormalities,
to ensure that no higher grade of dysplasia is present in the
esophagus. Most experts use HGD as a threshold for
therapeutic intervention or intensive surveillance.3 As such,
any areas of active inflammation within the BE segment should
be sampled. Conversely, our data indicate that the subset of
patients with IND but without active inflammation or flow
cytometric DNA content abnormalities can be spared from
repeat endoscopic surveillance for at least 3 years.
One limitation of our study is that only 39 (41%) of the 96 IND
patients had concurrent DNA flow cytometric analysis,
primarily because there is no established guideline on the
appropriate use of DNA flow cytometry for the management of
BE patients. However, despite the small sample size with
complete DNA flow cytometric data, the statistical power
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proved to be sufficient, as our results still showed a statistically
significant association with subsequent detection of LGD,
HGD, or EACwithout imputation aswell aswith both endpoints
(LGD/HGD/EAC and HGD/EAC) with imputation. For the
combined markers that used either a DNA flow cytometric
abnormality or active inflammation, only 23 patients had
uncertain classification due to missing DNA flow cytometric
data. Furthermore, a conservative analysis that classifies
patients with missing DNA flow cytometric measurements as
negative for DNA content abnormalities may be more
representative of most community and academic clinical
practices that may not have easy access to a DNA flow
cytometry laboratory. Clinicians are still faced with manage-
ment decisions in the absence of this information, and the
misclassification/conservative analyses (Figures 2 and 4)
demonstrate the high predictive value that can be expected, on
average, when some patients are missing DNA flow cyto-
metric data and active inflammation is considered (HR= 5.7
for detection of LGD, HGD, or EAC under misclassification;
HR= 4.8 for detection of HGDor EAC under misclassification).
In other words, more frequent endoscopic surveillance can be
justified for the early detection of neoplasia in IND patientswith
active inflammation, despite missing DNA flow cytometric
data. However, it should be noted that an imputation
(unbiased) method allows one to avoid bias from missing
data but does not allow one to makeup for the variability (large
CIs) that is inherent in a smaller sample size. Yet, the median
time to both endpoints (LGD/HGD/EAC and HGD/EAC) would
still be centered on the correct estimate.
Another possible limitation of our study is that all the IND
patients in this cohort were referred to or seen at the University
of Washington and Harborview Medical Centers, which
implies that referral bias cannot be ruled out, but the direction
of such bias, if it exists, is difficult to predict in this situation.
Despite these possible limitations, the data presented here
provide important information regarding the early detection of
dysplasia or EAC in a subset of IND patients with active
inflammation and/or DNA flow cytometric abnormalities.
Considering that the management of IND with endoscopic
surveillance and/or medical treatment (including proton pump
inhibitor) varies depending on the patients’ symptoms,
medication dose/compliance rates, and other variables, the
significance of our results seems even more remarkable,
because this may be much more representative of what is
happening in the real world. In conclusion, our findings support
the use of both histology and DNA flow cytometry to identify a
subset of patients with IND who may be at increased risk for
subsequent detection of dysplasia or EAC. These findings
would support the further study on the utility of more frequent
endoscopic surveillance for the early detection of dysplasia or
EAC in patients with IND.
CONFLICT OF INTEREST
Guarantor of the article: Maria Westerhoff, MD andWon-Tak
Choi, MD, PhD.
Specific author contributions: WTC, MJE, PSR, JA, MPU,
and MW contributed to the study concept and design,
acquisition of data, analysis and interpretation of data, and
drafting and revision of the manuscript. MJE also contributed
to statistical analysis. All authors have approved the final draft
submitted.
Financial support: None.
Potential competing interests: None.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Dysplasia arising from Barrett’s esophagus precedes
esophageal adenocarcinoma (EAC).
✓ Cases that are difficult to diagnose as dysplastic may be
designated “indefinite for dysplasia (IND)”.
✓ There are few reports that have specifically evaluated the
outcome of IND.
✓ Neither the American College of Gastroenterology nor the
American Gastroenterological Association’s practice
guidelines have specific recommendations for the
management of IND.
WHAT IS NEW HERE
✓ The 1-, 2-, and 3-year detection rates of neoplasia
(including low-grade dysplasia, high-grade dysplasia
(HGD), or EAC) were 25%, 37%, and 47%, respectively.
✓ Twenty percent of IND cases had detection of HGD or EAC
within 3 years.
✓ Active inflammation and DNA flow cytometric abnormalities
are significant predictors of neoplasia on subsequent
biopsies.
✓ A combination of DNA flow cytometric abnormality and
active inflammation is even more highly predictive of
detection of neoplasia within 3 years.
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